Loading...
  • inhibitor CB-839
  • The clinical trials on this list are studying Glutaminase Inhibitor CB-839. (cancer.gov)
  • This is a Phase 1b / 2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor CB-839 with the PARP inhibitor talazoparib in participants with advanced / metastatic solid tumors. (cancer.gov)
  • This phase I / II trial studies the side effects and best dose of glutaminase inhibitor CB-839 hydrochloride, and to see how well it works when given together with osimertinib in treating patients with stage IV non-small cell lung cancer and a mutation in the EGFR gene. (cancer.gov)
  • Glutaminase inhibitor CB-839 hydrochloride and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. (cancer.gov)
  • This phase I / II trial studies the best dose and side effects of glutaminase inhibitor CB-839 and how well it works with panitumumab and irinotecan hydrochloride in treating patients with RAS wildtype colorectal cancer that has spread to other places in the body and does not respond to treatment. (cancer.gov)
  • Giving glutaminase inhibitor CB-839 with panitumumab and irinotecan hydrochloride may work better in treating patients with colorectal cancer. (cancer.gov)
  • This phase I / II trial studies the side effects of glutaminase inhibitor CB-839 in combination with azacitidine in treating patients with myelodysplastic syndrome that has spread to other places in the body. (cancer.gov)
  • This phase I / II trial studies the side effects and best dose of glutaminase inhibitor CB-839 and capecitabine and to see how well they work in treating patients with solid tumors that have spread to other places in the body or colorectal cancer. (cancer.gov)
  • Combination treatment with the first-in-class glutaminase inhibitor CB-839 and nivolumab shows promise for overcoming anti-PD-1/PD-L1 resistance. (mdedge.com)
  • NATIONAL HARBOR, MD. - Combination treatment with the first-in-class glutaminase inhibitor CB-839 and nivolumab is well-tolerated and shows clinical activity in patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer, including anti-PD-1/PD-L1 refractory patients, according to initial results from a phase 1/2 study. (mdedge.com)
  • Here, we developed a robust, highly repeatable GluCEST MRI protocol in mice bearing human TNBC xenografts and treated with a potent glutaminase inhibitor, CB-839. (aacrjournals.org)
  • PSEUDOMONAS
  • Deamidase AG (asparaginase-glutaminase) was obtained from Pseudomonas fluorescens in a crystalline apparently homogenous state. (msk.ru)
  • mice
  • Synaptic underpinnings of altered hippocampal function in glutaminase-deficient mice during maturation. (nih.gov)
  • Known
  • This model is based on selected known glutaminases and their homologs within prokaryotes, with the exclusion of highly-derived (long-branch) and architecturally varied homologs, so as to achieve conservative assignments. (worldheritage.org)
  • cell
  • Effects of single and combined treatments with acivicin and glutaminase on angiogenic factors were also analyzed in these cell lines. (niscair.res.in)